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Background: The study was designed to explore the regular patterns of level V lymph node metastasis (LNM) in
papillary thyroid carcinoma (PTC), and to indicate whether level V should be included in the management of lateral
neck dissection when treating PTC.
Methods: This retrospective study consisted of 330 patients diagnosed with PTC from January 1994 to July 2009
who underwent an operation that included therapeutic lateral neck dissection (levels II to V). The patterns of lateral
neck LNM were analyzed and the relevant risk factors of level V LNM were analyzed with univariate and multivariate
analysis, respectively.
Results: All the patients underwent lateral neck dissection at levels II to V. The predominant site of metastasis was
level III (247/330 (74.8%)), followed by level IV (233/330 (70.6%)), and level II (215/330 (65.3%)). Simultaneous
multilevel involvement (level II, III, and IV) of lymphatic metastases presented in 46.1% (152/330) of the cases. Level
V showed 28.8% (95/330) of nodal metastasis. Multivariate analysis showed that level V LNM was significantly
associated with location (whole thyroid), gross extrathyroidal extension and simultaneous multilevel involvement
(level II, III and IV). (P <0.05).
Conclusions: Due to relatively high rate of level V involvement and its correlation with location (whole thyroid),
gross extrathyroidal extension and multilevel involvement, we consider that it may be more rational to include level
V in the therapeutic lateral neck dissection when treating PTC, especially for those who have any one of these three
independent risk factors.
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Papillary thyroid carcinoma (PTC) seems to display a pe-
culiar characteristic in which some biological discrepan-
cies exist between clinical and subclinical cancers. For
example, although the prevalence of microcarcinoma in
autopsy series has been reported up to 36% among the
general population, clinical prevalence of PTC is 0.1% at
the most. The patients with PTC have a relatively
excellent prognosis with a 10-year overall survival rate
exceeding 90%. However, cervical lymph node metastasis
are found in 30 to 80% of patients when diagnosed,* Correspondence: chenwk@sysucc.org.cn
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reproduction in any medium, provided the orincluding occult metastases [1]. Cervical LNM in PTC
has been found to be one of the most significant factors
for locoregional recurrence, and it also has been
regarded as the first sign of a potentially lethal outcome
[2-5]. Therefore, an effective therapeutic lateral neck dis-
section is critical. However, overly aggressive operations
such as blindly enlarging the extent of lateral neck dis-
section may lead to clinically important postoperative
morbidities because of injury to the spinal accessory
nerve or the cervical plexus, despite gross preservation
of these nerves [6,7]. Consequently, it is of great clinical
significance to extensively and deeply understand the
regular patterns of cervical LNM, which could indicate
the rational extent of lateral neck dissection in the treat-
ment of PTC.
At present, most scholars agree that therapeutic or
prophylactic central neck dissection should be routinelyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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unfortunately, the extent of dissection remains contro-
versial. Patients of PTC with lateral neck lymph node
metastases should undergo therapeutic lateral neck dis-
section. Generally, the extent of therapeutic lateral neck
dissection includes level II to V. However, some authors
suggested that routine level V lymphadenectomy was
not necessary for the treatment of patients with PTC
who have clinically positive lateral neck lymph node me-
tastases because of the relatively low metastases rate of
lymph nodes in level V [8]. Another opinion is that PTC
is associated with LNM in 30 to 80% of patients patho-
logically, while nodal recurrence in patients not receiv-
ing prophylactic dissection is reportedly less than 10%.
The aim of this study was to explore the regular patterns
of lateral neck LNM and suggest the rational manage-
ment of lateral neck dissection in treatment of PTC:
should level V be included in lateral neck dissection in
the treatment of papillary thyroid carcinoma?
Methods
We collected clinical data of 330 patients with PTC from
January 1994 to Jul 2009 in Sun Yat-sen University
Cancer Center. The Institutional Review Board of Sun
Yat-sen University Cancer Center approved the study.
All patients received initial treatment of therapeutic lat-
eral neck dissection at level II to V for treatment of
clinically positive lateral neck nodal metastases. Physical
examination, thyroid ultrasonography (US) and neck
computed tomography (CT) were performed for pre-
operative evaluation of the primary thyroid tumors and
suspicious lateral neck lymph nodes, and PTC and lat-
eral neck lymph node metastasis were both confirmed
pathologically by fine-needle aspiration cytology or
intraoperative frozen section. All neck dissection speci-
mens were separated by regions for pathological analysis.
The patterns of lateral neck LNM were analyzed. Also
the relevant risk factors of level V LNM were analyzed,
with univariate and multivariate analysis, respectively.
The ‘respectively’ refers to ‘the relevant risk factors of
level V LNM’ only. All of the 330 patients received thy-
roidectomy (total or lobectomy plus isthmusectomy) to-
gether with central neck dissection and therapeutic
lateral neck dissection (levels II to V). Indications for
total thyroidectomy are mainly based on the convention-
ally high-risk factors, including age younger than 15 years
or older than 45 years, radiation history, known distant
metastases, cervical lymph node metastases, extrathyroi-
dal extension, tumor greater than 4 cm in diameter,
bilateral nodularity, or aggressive variants like tall cell,
columnar cell or diffuse sclerosing variant. Patients
without above high-risk factors received lobectomy plus
isthmusectomy. Of those patients, 29 patients underwent
bilateral lateral neck dissection. All neck dissectionspecimens were recorded according to regions, but only
the ipsilateral specimens were analyzed in this study
when bilateral lateral neck dissection was performed.
Within a median follow-up of 8.9 years (4.0 to
18.0 years), 12.1% (40/330) of this patient cohort has
tumor recurrences; up to 75% (30/40) of these recur-
rences were seen in cervical lymph nodes, and 25%
(10/40) were seen in thyroid remnants. Distant metasta-
ses were seen in 3.3% (11/330), most often (72.7%) in
lungs. 4.2% (14/330) of cases resulted in cancer-related
death. The changes did not alter intended meaning of
the previous sentence.
Statistical analyses were performed using SPSS ver.
13.0 (SPSS Inc., Chicago, IL, USA). Univariate analyses
for the associations between level V lymph node metas-
tases and clinicopathologic factors of thyroid carcinoma
were performed using Pearson Chi-square test. Multi-
variate analysis was performed using Binary logistic
regression analysis. A P value of less than 0.05 was con-
sidered statistically significant.Results
Of these 330 patients with PTC that involved lateral
neck lymph node metastases, 140 were male and 190
were female. The median age was 35.0 years (range, 8 to
75 years) and there were 243 (73.6%) patients who were
younger than 45 years. The number of patients with soli-
tary and multifocal lesion of primary tumor were 248
(75.2%) and 82 (24.8%), respectively (Table 1).
As to the lateral neck lymph node metastases, the
predominant site of metastasis was level III (247/330
(74.8%)), followed by level IV (233/330 (70.6%)),
and level II (215/330 (65.3%)). Level V showed 28.8%
(95/330) of nodal metastasis. Single level involvement
was seen in 68 (20.6%) cases. Simultaneous multilevel in-
volvement (level II, III, and IV) of lymphatic metastases
was seen in 152 (46.1%) cases. Univariate analysis of risk
factors related to level V LNM demonstrated that, level
V LNM was associated with location, gross extrathyroi-
dal extension and simultaneous multilevel involvement
(level II, III, and IV) of lymphatic metastases (P <0.05,
Table 2). In multivariate analysis, level V LNM was sig-
nificantly associated with location (whole thyroid), gross
extrathyroidal extension and simultaneous multilevel in-
volvement (level II, III and IV) (P <0.05, Table 3).Discussion
As an excellent prognosis for patients with PTC is pos-
sible, increasingly, doctors and patients have begun to
pursue the second aim: decreasing recurrence and
chance of second operation and improving the patients’
quality of life. Early cervical lymph node metastasis is
one of the most remarkable features in PTC. Therefore,
Table 1 Patients’ demographics
Variable Value Ratio (%)
Gender Male 140 42.4
Female 190 57.6
Age (years) <45 243 73.6
≥45 87 26.4
Locationa left lobe 120 36.4
right lobe 152 46.1
whole thyroid 58 17.5
Lesion solitary lesion 248 75.2
multifocal lesion 82 24.8
Intact capsuleb Yes 292 88.5
No 38 11.5
Gross Ex Yes 39 11.8
No 291 88.2
Tumor size (cm) ≤1 56 17.0
>1, ≤ 2 140 42.4
>2, ≤ 4 117 35.5
>4 17 5.2
Local recurrences Yes 40 12.1
No 290 87.9
Distant metastases Yes 11 3.3
No 319 96.7
Death Yes 14 4.2
No 316 95.8
aThe site of primary papillary thyroid carcinoma (PTC).
bIntact capsule means that tumor have not extended through its capsule.
Gross Ex, gross extrathyroidal extension.
Table 2 Univariate analysis of factors related to level V
lymph node metastasis (LNM) in 330 patients with
papillary thyroid carcinoma (PTC)
Variable Cases LNM or Not P value
Age <45 yr 243 66 177 0.275
≥45 yr 87 29 58
Gender Male 140 47 93 0.099
Female 190 48 142
Locationa Left lobe 120 29 91 0.000
Right lobe 152 37 115
Whole thyroid 58 29 29
Lesion Solitary lesion 248 67 181 0.216
Multifocal lesion 82 28 54
Intact capsuleb Yes 292 81 211 0.244
No 38 14 24
Gross Ex Yes 39 17 22 0.030
No 291 78 213
Tumor size (cm) ≤1 56 12 44 0.170
1 ≤2 140 44 96
2 ≤4 117 31 86
>4 17 8 9
Simultaneous Yes 152 53 99 0.024
metastasesc No 178 42 136
aThe site of primary PTC.
bIntact capsule means that tumor have not extended through its capsule.
cSimultaneous metastases including level II, III and IV.
Gross Ex, gross extrathyroidal extension.
Table 3 Multivariate analysis of factors related to level V
lymph node metastasis (LNM) in 330 patients with
papillary thyroid carcinoma (PTC)
Variable P value Risk ratios 95.0% C.I.
Locationa 0.002 0.591 0.421 to 0.829
Gross Exb 0.049 2.014 1.004 to 4.038
Simultaneous metastasesc 0.004 2.074 1.271 to 3.385
aThe site of primary PTC.
bGross extrathyroidal extension.
cSimultaneous metastases including level II, III and IV.
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eral lymph nodes.
There are various options in the extent of therapeutic
lateral neck dissection in PTC. Whether or not level V
should be included in the lateral neck dissection con-
tinues to be debated [9,10].
In this study, the predominant site of metastasis was
level III (247/330 (74.8%)), followed by level IV (233/330
(70.6%)), and level II (215/330 (65.3%)). The incidence of
simultaneous multilevel involvement of lymphatic me-
tastases was as high as 46.1%, which was in accordance
with the data reported in literature [11]. Hence, at least
level II through IV should be included in the therapeutic
lateral neck dissection if the lateral neck lymph nodes
were positive.
Young Chang Lim et al. [8] reported that occult me-
tastases in level V were observed in 11/70 (16%) pa-
tients, and it was not appropriate to routinely perform
Level V lymphadenectomy. But Kupferman et al. [12]
believed that routine dissection of the level V lymph
nodes was necessary in the therapeutic lateral neck dis-
section. In this study, level V showed 28.8% (95/330) ofnodal metastasis and agreed with the incidence of ap-
proximately 16.7 to 53% reported in literature [11-16].
Multivariate analysis indicated that location (whole thy-
roid), gross extrathyroidal extension and simultaneous
multilevel involvement (level II, III, and IV) of lymphatic
metastases were the independent risk factors of level V
LNM (Table 3), which was similar to the results reported
in the literature [12,13,17]. In a word, due to both the
relatively high incidence (28.8%) of level V LNM and in-
cidence (46.1%) of simultaneous multilevel involvement
(level II, III, and IV) of lymphatic metastases in this
study, we consider that it may be more rational to in-
clude level V in the therapeutic lateral neck dissection,
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thyroid, or when gross extrathyroidal extension or multi-
level involvement are present.
Considering that this is a retrospective study and in-
formation in the pathological report is limited, we failed
to separate the analysis for levels Va and Vb. We will
analyze the levels in our further studies. Nevertheless,
we present a larger sample size in this study and demon-
strate a reliable result in the management of level V
when therapeutic lateral neck dissection was performed
for the treatment of PTC.
Conclusions
In summary, due to relatively high rate of level V in-
volvement and its correlation with location (whole thy-
roid), gross extrathyroidal extension and multilevel
involvement, we consider that it may be more rational
to include level V in the therapeutic lateral neck dissec-
tion when treating PTC, especially for those who have
any one of these three independent risk factors.
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